Guardian Wealth Management Inc. Buys 4,391 Shares of Johnson & Johnson (NYSE:JNJ)

Guardian Wealth Management Inc. raised its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 48.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,492 shares of the company's stock after acquiring an additional 4,391 shares during the period. Johnson & Johnson makes up 1.5% of Guardian Wealth Management Inc.'s portfolio, making the stock its 29th largest holding. Guardian Wealth Management Inc.'s holdings in Johnson & Johnson were worth $2,238,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of JNJ. WealthTrak Capital Management LLC bought a new position in Johnson & Johnson during the fourth quarter valued at approximately $26,000. Conquis Financial LLC bought a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $33,000. Bernard Wealth Management Corp. purchased a new position in shares of Johnson & Johnson in the fourth quarter valued at $36,000. Highline Wealth Partners LLC increased its position in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after purchasing an additional 86 shares during the last quarter. Finally, von Borstel & Associates Inc. purchased a new stake in Johnson & Johnson during the first quarter valued at $49,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Up 0.3%

Shares of NYSE:JNJ traded up $0.52 during trading on Thursday, reaching $169.62. 6,629,361 shares of the company were exchanged, compared to its average volume of 8,401,730. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The firm has a market capitalization of $408.11 billion, a PE ratio of 18.14, a P/E/G ratio of 2.15 and a beta of 0.41. The business's fifty day simple moving average is $155.75 and its 200-day simple moving average is $155.63. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same period last year, the business posted $2.82 EPS. Johnson & Johnson's quarterly revenue was up 5.8% on a year-over-year basis. On average, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.07%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on JNJ shares. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Raymond James Financial decreased their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Wall Street Zen cut Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. Morgan Stanley raised their price target on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Finally, Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Nine equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $174.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.